Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Editas Medicine (EDIT) Long-Term Debt Repayments (2015 - 2025)

Editas Medicine (EDIT) reported Long-Term Debt Repayments of $2.9 million for Q1 2025, up 1116.95% on a QoQ basis from $236000.0 in Q4 2018.

Editas Medicine (EDIT) has 4 years of Long-Term Debt Repayments data on file, last reported at $2.9 million in Q1 2025.

  • Quarterly Long-Term Debt Repayments changed N/A year-over-year to $2.9 million in Q1 2025, while the trailing twelve-month figure through Sep 2025 was $2.9 million (up 1116.95% YoY) and the FY2018 annual result came in at $857000.0, up 12.17% from the prior year.
  • Long-Term Debt Repayments grew to $2.9 million in Q1 2025 per EDIT's latest filing, from $236000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $2.9 million in Q1 2025 and bottomed at $2.9 million in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Editas Medicine 338.62 Mn 338.62 Mn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2025 2.87 Mn
Mar 31, 2025 2.87 Mn
Dec 31, 2018 236,000.00
Dec 31, 2018 236,000.00
Sep 30, 2018 211,000.00
Sep 30, 2018 211,000.00
Jun 30, 2018 207,000.00
Jun 30, 2018 207,000.00
Mar 31, 2018 203,000.00
Mar 31, 2018 203,000.00
Sep 30, 2017 600,000.00
Sep 30, 2017 600,000.00
Jun 30, 2017 390,000.00
Jun 30, 2017 390,000.00
Mar 31, 2017 443,000.00
Mar 31, 2017 443,000.00
Dec 31, 2015 1.93 Mn
Dec 31, 2015 1.93 Mn
Sep 30, 2015 42,000.00
Sep 30, 2015 42,000.00